Skip to main content
SpringerLink
Log in

Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson’s disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449–450

  • Commentary
  • Published:
Psychopharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  • Baggott M, Mendelson J, Jones R (1999) More about parkinsonism after taking ecstasy. N Engl J Med 341:1400–1401

    Article  CAS  Google Scholar 

  • Borg GJ (1999) More about parkinsonism after taking ecstasy. N Engl J Med 341:1401

    Article  Google Scholar 

  • Cohen RS (1995) Subjective reports on the effects of the MDMA (“ecstasy”) experience in humans. Progr Psychopharmacol Biol Psychiatry 19:1137–1145

    Article  CAS  Google Scholar 

  • Fox HC, Parrott AC, Turner JJD (2001) Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug. J Psychopharmacol 15:273–281

    CAS  PubMed  Google Scholar 

  • Gill JR, Hayes JA, deSouza IS, Marker E, Stajic M (2003) Ecstasy (MDMA) deaths in New York City: a case series and review of the literature. J Forensic Sci 47:121–126

    Google Scholar 

  • Gore SM (1999) Fatal uncertainty: death rate from use of ecstasy or heroin. Lancet 354:1265–1266

    Article  CAS  PubMed  Google Scholar 

  • Heffernan TM, Jarvis H, Rodgers J, Scholey AB, Ling J (2001) Prospective memory, everyday cognitive failure and central executive function in recreational users of ecstasy. Hum Psychopharmacol Clin Exp 16:607–612

    Article  Google Scholar 

  • Henry JA, Rella JG (2001). Medical risks associated with MDMA use. In Holland J (ed) Ecstasy: the complete guide. Inner Traditions, Rochester, VT

    Google Scholar 

  • Holden C (2002) Neuroscience: drug find could give ravers the jitters. Science 297:2185–2187

    Google Scholar 

  • Kish SJ, Furukawa Y, Ang L, Vorce SP, Kalasinsky KS (2000) Striatal serotonin is depleted in brain of a human MDMA (ecstasy) user. Neurology 55:294–296

    CAS  PubMed  Google Scholar 

  • McCann UD, Ridenour A, Shaham Y, Ricaurte GA (1994) Serotonin neurotoxicity after (+/-) 3,4-methylenedioxymethamphetamine (MDMA; “ecstasy”): a controlled study in humans. Neuropsychopharmacology 10:129–138

    CAS  PubMed  Google Scholar 

  • McCann UD, Mertl M, Eligulashvili V, Ricaurte GA (1999) Cognitive performance in (+/−) 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) users: a controlled study. Psychopharmacology 143:417–425

    CAS  PubMed  Google Scholar 

  • Mintzer S, Hickenbottom S, Gilman S (1999) Parkinsonism after taking ecstasy. N Engl J Med 340:1443

    Article  CAS  Google Scholar 

  • Parrott AC, Lasky J (1998) Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology 139:261–268

    Article  CAS  PubMed  Google Scholar 

  • Parrott AC, Buchanan T, Scholey AB, Heffernan T, Ling J, Rodgers J (2002) Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users. Hum Psychopharmacol 17:309–312

    Article  CAS  PubMed  Google Scholar 

  • Reneman L, Booij J, Lavalaye J, de Bruin K, Reitsma JB, Gunning B, den Heeten GJ, van Den Brink W (2002) Use of amphetamine by recreational users of ecstasy (MDMA) is associated with reduced striatal dopamine transporter densities: a [123I]beta-CIT SPECT study—preliminary report. Psychopharmacology 159:335–340

    Article  CAS  PubMed  Google Scholar 

  • Ricaurte GA, DeLanney LE, Irwin I, Langston JW (1988) Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res 446:165–168

    CAS  PubMed  Google Scholar 

  • Ricaurte GA, Finnegan KT, Irwin I, Langston JW (1990) Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: preliminary observations. Ann N Y Acad Sci 600:699–710

    CAS  PubMed  Google Scholar 

  • Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD (2002) Severe Dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA (“ecstasy”). Science 297:2260–2263

    Article  CAS  PubMed  Google Scholar 

  • Rodgers J (2000) Cognitive performance amongst recreational users of “ecstasy.” Psychopharmacology 151:19–24

    Google Scholar 

  • Semple DM, Ebmeier KP, Glabus MF, O’Carroll RE, Johnstone EC (1999) Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (‘ecstasy’) users. Br J Psychiatry 175:63–69

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Public Health, Liverpool John Moores University, 70 Great Crosshall Street, Liverpool, L3 2AB, UK

    H. R. Sumnall

  2. Multidisciplinary Association for Psychedelic Studies, 2105 Robinson Avenue, Sarasota, FL 34232, USA

    L. Jerome & R. Doblin

  3. 208 Scott Street, Mt. Pleasant, SC 29464, USA

    M. C. Mithoefer

Authors
  1. H. R. Sumnall
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Jerome
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Doblin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. C. Mithoefer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. R. Sumnall.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sumnall, H.R., Jerome, L., Doblin, R. et al. Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson’s disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449–450. Psychopharmacology 171, 229–230 (2004). https://doi.org/10.1007/s00213-003-1599-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-003-1599-3

Keywords

Search

Navigation